New mutation-testing technology has potential to guide targeted lung and colorectal cancer therapies

June 08, 2016

Philadelphia, PA, June 8, 2016 - A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.

The identification and functional analysis of tumor-specific genetic alterations suggest opportunities to exploit genetic mutations as predictors of therapeutic response and guide a more effective patient treatment regime. KRAS mutations represent a powerful biomarker for predicting treatment sensitivity in patients with non-small-cell lung cancer and colorectal cancer. The protein product of the normal KRAS gene is involved primarily in regulating cell division.

"Targeted therapies are a growing trend in basic and clinical cancer research, and for good reason -- the potential for improved treatment outcomes and cost savings is tremendous," explained lead investigator Kimberly A. Kelly, PhD, of the Department of Biomedical Engineering, University of Virginia, Charlottesville, VA. "However, the effective implementation of a targeted therapeutic regime requires a practical means for preemptive molecular characterization of the cancer. In an effort to fulfill the unmet clinical demand for a methodology amenable to the requirements of routine testing, we developed a novel approach that provides simple, rapid, and inexpensive detection of point mutations."

Conventional mutation testing technologies are not ideal for routine clinical screening of KRAS mutations because they often involve complex, time-consuming processes and/or costly instrumentation. Investigators have therefore developed and tested a new technique for lung and colorectal cancer samples that can be used in routine testing.

The new technique described in the study uses hybridization-induced aggregation (HIA) technology for mutation detection (HIAMD), which enables the detection of common KRAS mutations in less than 10 minutes following PCR amplification. HIA is a bead-based DNA-detection technology that is scalable for a microchip platform.

The investigators analyzed 20 lung and colorectal tumors and compared the results using this new technique with results from the more expensive and cumbersome sequencing method. The results of KRAS mutation screening using this technique were 100% in agreement with the results derived from sequencing. In addition, a sample with only 25% KRAS mutant content could be detected in a background of wild-type DNA, consistent with the detection limit reported using the sequencing method.

"These results indicate the validity of HIAMD as a mutation-testing technology suitable for practical clinical testing," said Dr. Kelly. "Importantly, the analysis is performed in a manner that is both rapid and cost effective. The current direction of clinical oncology research suggests that a technology such as HIAMD will continue to be a highly relevant and valued analytical tool for the facilitation of individualized therapeutic strategies, and the successes here indicate the potential to apply this technology for the routine analysis of other important genetic markers."

Elsevier Health Sciences

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to